The concomitant use of sodium-glucose co-transporter 2 inhibitors improved the renal outcome of Japanese patients with type 2 diabetes treated with glucagon-like peptide 1 receptor agonists.
Kobayashi K, Toyoda M, Hatori N, Tsukamoto S, Kimura M, Sakai H, Furuki T, Chin K, Kanaoka T, Aoyama T, Umezono T, Ito S, Suzuki D, Takeda H, Degawa H, Hishiki T, Shimura H, Nakajima S, Miyauchi M, Yamamoto H, Hatori Y, Hayashi M, Sato K, Miyakawa M, Terauchi Y, Tamura K, Kanamori A.
Kobayashi K, et al. Among authors: kanaoka t.
Cardiovasc Endocrinol Metab. 2023 Sep 28;12(4):e0292. doi: 10.1097/XCE.0000000000000292. eCollection 2023 Dec.
Cardiovasc Endocrinol Metab. 2023.
PMID: 37779602
Free PMC article.